OncoMatch/Clinical Trials/NCT07391657
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Is NCT07391657 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for relapsed refractory multiple myeloma.
Treatment: AZD0120 · Daratumumab · Carfilzomib · Dexamethasone · Bortezomib · Pomalidomide — This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, bortezomib and dexamethasone\], or Kd \[carfilzomib and dexamethasone\]) in participants with RRMM.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: immunomodulatory drug
Received 1 to 3 lines of prior therapy including an IMiD and either a PI or a CD38 antibody
Must have received: proteasome inhibitor
Received 1 to 3 lines of prior therapy including an IMiD and either a PI or a CD38 antibody
Must have received: CD38 antibody
Received 1 to 3 lines of prior therapy including an IMiD and either a PI or a CD38 antibody
Cannot have received: BCMA-targeted therapy
Previously received any prior BCMA-targeted treatment
Cannot have received: CAR-T cell therapy
Previously received CAR-T or CAR-NK therapy directed at any target
Cannot have received: CAR-NK cell therapy
Previously received CAR-T or CAR-NK therapy directed at any target
Cannot have received: T-cell engager therapy
Previously received T-cell engager therapy directed at any target
Cannot have received: allogeneic stem cell transplant
Previously received allogeneic stem cell transplantation at any time during prior therapy
Cannot have received: autologous stem cell transplant
Exception: within 12 weeks of randomization
received autologous stem cell transplantation within 12 weeks of randomization
Lab requirements
Blood counts
Haemoglobin ≥ 8.0 g/dL; Absolute neutrophil count ≥ 1 × 10^9/L (1000 per mm3); Platelet count ≥ 75 × 10^9/L (75000 per mm3) in participants with < 50% of bone marrow nucleated cells are plasma cells or ≥ 50 × 10^9/L (50000 per mm3) in participants with ≥ 50% of bone marrow nucleated cells are plasma cells; Absolute lymphocyte count ≥ 300/µL (0.3 × 10^9/L)
Kidney function
CrCl by Cockcroft and Gault method ≥ 30 mL/minute
Liver function
Total bilirubin ≤ 1.5 × ULN in the absence of Gilbert's syndrome or ≤ 3 × ULN if the participant has Gilbert's syndrome. AST and ALT≤ 3.0 × ULN.
Adequate hematology and chemistry laboratory values
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Gilbert, Arizona
- Research Site · Phoenix, Arizona
- Research Site · Tucson, Arizona
- Research Site · La Jolla, California
- Research Site · Santa Monica, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify